Effects of once-daily use of inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) on the lung function in Japanese patients with ssthma

Effects of once-daily use of inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) on the lung function in Japanese patients with ssthma - Lung function change by FF/VI

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034466

Enrollment

150

Registered

2018-10-12

Start date

2014-09-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Interventions

Prior treatments of asthma (twice-daily use of inhaled steroids with or without long-acting beta-2 agonists) were changed to once-daily use of fluticasone furoate (FF)/vilanterol(VI) (200 microgram/25

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with astmam had to be already satisfied with their current treatment with regular maintenance inhalation therapy with inhaled corticosteroid (ICS) alone or ICS combined with a long acting beata-2 agonist.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Change of lung function test data	—

Secondary

Measure	Time frame
Questions on the control of asthma, side effects, and preference of drug are asked.	—

Countries

Japan

Contacts

Public ContactMasato Takahashi

International University of Health and Welfare Hospital Ethics Committee

masa-takahashi@iuhw.ac.jp0287-39-3060

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026